Literature DB >> 32405810

Prognostic significance of T1 mapping parameters in heart failure with preserved ejection fraction: a systematic review.

Abdelmoniem Moustafa1, Mohammad Saud Khan1, Mohd Amer Alsamman1, Faisal Jamal2, Michael K Atalay3,4.   

Abstract

Heart failure with preserved ejection fraction (HFpEF) accounts for almost one-half of all heart failure (HF) patients and continues to increase in prevalence. While mortality with heart failure with reduced ejection fraction (HFrEF) has decreased over the past few decades with use of evidence-based HFrEF therapy, mortality related to heart failure with HFpEF has not changed significantly over the same time period. The combination of poor prognosis and lack of effective treatment options creates a pressing need for novel strategies for better patient characterization. We conducted a systematic review to evaluate the prognostic value of cardiac magnetic resonance (CMR)-derived T1 relaxation time and extracellular volume fraction (ECV) in HFpEF patients. PubMed, Embase, and Cochrane Central were searched for relevant studies. The primary outcomes of interest were hospitalization for HF and all-cause mortality. Five studies with 2741 patients were included. Four studies reported correlation of outcomes with ECV, 2 studies reported correlation of outcomes with native T1 time, and 1 study reported correlation of outcomes with post-contrast T1 time. All five studies showed significant correlation of CMR-derived parameters with adverse outcomes including event-free survival to cardiac event, all cause, and cardiac mortality. CMR-determined ECV is strongly correlated with adverse outcomes in HFpEF cohorts.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CMR; ECV; Extracellular volume fracture; HFpEF; T1 mapping

Mesh:

Year:  2021        PMID: 32405810     DOI: 10.1007/s10741-020-09958-4

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  1 in total

Review 1.  A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease.

Authors:  Lu Fang; Andrew J Murphy; Anthony M Dart
Journal:  Front Pharmacol       Date:  2017-04-06       Impact factor: 5.810

  1 in total
  3 in total

1.  Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction.

Authors:  Pankaj Garg; Hosamadin Assadi; Rachel Jones; Wei Bin Chan; Peter Metherall; Richard Thomas; Rob van der Geest; Andrew J Swift; Abdallah Al-Mohammad
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

Review 2.  Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction.

Authors:  Dane Rucker; Jacob Joseph
Journal:  Curr Heart Fail Rep       Date:  2022-09-30

3.  Myocardial fibrosis in patients with a history of Kawasaki disease.

Authors:  Susan M Dusenbery; Jane W Newburger; Steven D Colan; Kimberlee Gauvreau; Annette Baker; Andrew J Powell
Journal:  Int J Cardiol Heart Vasc       Date:  2021-01-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.